PL436634A1 - Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie - Google Patents

Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Info

Publication number
PL436634A1
PL436634A1 PL436634A PL43663421A PL436634A1 PL 436634 A1 PL436634 A1 PL 436634A1 PL 436634 A PL436634 A PL 436634A PL 43663421 A PL43663421 A PL 43663421A PL 436634 A1 PL436634 A1 PL 436634A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
preparation
triglycerides
filler
Prior art date
Application number
PL436634A
Other languages
English (en)
Other versions
PL244822B1 (pl
Inventor
Michał Kołodziejczyk
Michał Nachajski
Justyna KOŁODZIEJSKA
Małgorzata GODLEWSKA
Original Assignee
Jezierska Monika Celvet Spółka Cywilna
Marczak Monika Celvet Spółka Cywilna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jezierska Monika Celvet Spółka Cywilna, Marczak Monika Celvet Spółka Cywilna filed Critical Jezierska Monika Celvet Spółka Cywilna
Priority to PL436634A priority Critical patent/PL244822B1/pl
Priority to PCT/IB2022/050146 priority patent/WO2022149103A1/en
Publication of PL436634A1 publication Critical patent/PL436634A1/pl
Publication of PL244822B1 publication Critical patent/PL244822B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego zawierająca antybiotyk β-laktamowy, inhibitor β-laktamaz, substancję wypełniającą, przeciwutleniacz i substancję poprawiającą smak, charakteryzująca się tym, że substancją wypełniającą jest mieszanina triglicerydów kwasów tłuszczowych C8 i C10 oraz mono-, di- i triglicerydów kwasów tłuszczowych C8-C18, sposób wytwarzania takiej kompozycji oraz jej zastosowanie w leczeniu chorób bakteryjnych. Przedmiotem wynalazku jest również niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego zawierająca antybiotyk β-laktamowy, inhibitor β-laktamaz, substancję wypełniającą, substancję żelującą, przeciwutleniacz i substancję poprawiającą smak, charakteryzująca się tym, że substancja wypełniająca jest wybrana z grupy składającej się z triglicerydów kwasów tłuszczowych C8 i C10 i oleju oliwkowego, a substancją żelującą jest krzemionka koloidalna, sposób jej wytwarzania oraz zastosowanie w leczeniu chorób bakteryjnych.
PL436634A 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie PL244822B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL436634A PL244822B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie
PCT/IB2022/050146 WO2022149103A1 (en) 2021-01-11 2022-01-10 A non-aqueous pharmaceutical composition in the form of a suspension for oral administration, a process of preparing and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL436634A PL244822B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Publications (2)

Publication Number Publication Date
PL436634A1 true PL436634A1 (pl) 2022-07-18
PL244822B1 PL244822B1 (pl) 2024-03-11

Family

ID=80787361

Family Applications (1)

Application Number Title Priority Date Filing Date
PL436634A PL244822B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Country Status (2)

Country Link
PL (1) PL244822B1 (pl)
WO (1) WO2022149103A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103349659A (zh) * 2006-09-26 2013-10-16 塔罗制药北美有限公司 液体药物组合物以及应用
CN106265505B (zh) * 2016-11-11 2019-06-25 成都乾坤动物药业股份有限公司 一种阿莫西林克拉维酸钾油混悬剂及其制备方法

Also Published As

Publication number Publication date
WO2022149103A1 (en) 2022-07-14
PL244822B1 (pl) 2024-03-11

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
ZA202000425B (en) Selective inhibitors of nlrp3 inflammasome
PH12022553024A1 (en) Inhibitors of nek7 kinase
MX2024011317A (es) Procesos para la preparación de derivados sustituidos de espirooxindol.
EA200400595A1 (ru) Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
MY203711A (en) Afabicin formulation, method for making the same and uses thereof
PL436634A1 (pl) Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
WO2025014877A3 (en) Triazolo wrn inhibitors
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
WO2024254511A3 (en) Wrn inhibitors
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
AU2024326270A1 (en) Compositions and methods for the treatment of disorders related to frataxin deficiency
EA201001328A1 (ru) Оральные дозированные композиции и способ их получения
MY207295A (en) Method for preparing a composition comprising cetylated fatty acids
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
ZA202400821B (en) Inhibitors of transglutaminases
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
PL438764A1 (pl) Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
WO2020156501A8 (zh) 喹啉衍生物的结晶
ZA202400823B (en) Inhibitors of transglutaminases
MX2023015096A (es) Inhibidores de transglutaminasas.